Next-generation immunotherapy: igniting new hope for lung cancer DOI Creative Commons
Molly Li, Antony C. S. Chan, Kevin Mok

et al.

Therapeutic Advances in Medical Oncology, Journal Year: 2024, Volume and Issue: 16

Published: Jan. 1, 2024

Adoption of immunotherapy has completely transformed the treatment landscape cancer. Patients with advanced cancer treated may benefit from durable tumor response and long-term survival. The most widely used in solid tumors is anti-programmed-death (ligand) protein (PD-(L)1), which now an integral part non-small cell lung (NSCLC) irrespective histological types stage. However, vast majority patients NSCLC anti-PD-(L)1 still develop therapeutic resistance, prognosis after resistance poor. Resistance mechanisms to PD-1 blockade are often complex encompass a combination defects within cancer-immunity cycle. These include failure antigen presentation T-cell priming, presence co-inhibitory immune checkpoints, inability cells infiltrate tumor, immunosuppressive microenvironment. Recently, advances drug design, genomic sequencing, gene editing technologies have led development next-generation immunotherapies that potentially overcome these mechanisms. In this review, we will discuss mechanism four novel modalities detail, namely checkpoint inhibitor targeted therapy combinations, bispecific antibodies, vaccine, therapy. therapeutics all demonstrated early clinical data work synergistically each other restore anticancer immunity. addition, share our perspectives on future promises challenges transformation standard care.

Language: Английский

Advances in Vaccine-Based Therapies for Pancreatic Cancer DOI Creative Commons
Matthew T. McMillan, Kevin C. Soares

Journal of Gastrointestinal Cancer, Journal Year: 2025, Volume and Issue: 56(1)

Published: Feb. 12, 2025

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, with a 5-year survival rate that has improved only marginally over past 30 years, despite numerous clinical trials. PDAC poses several unique challenges, including early metastatic spread and predilection for liver metastasis. It is also highly resistant to anti-tumor immunity immunotherapy due its dense immunosuppressive tumor microenvironment, low immunogenicity, systemic immune suppression. mutational burden, defective antigen presentation, checkpoint molecule upregulation, which reduce recognition. Together, these factors leave as an "immune cold" minimal cytotoxic T-cell activity. Novel therapeutic approaches are urgently needed reinvigorate immunity. Recent advances, such adjuvant personalized mRNA neoantigen vaccines mutant-KRAS targeted vaccines, have demonstrated sustained vaccine-induced T cell responses associated recurrence-free in surgically resected PDAC. Combining different vaccine optimal sequencing chemotherapy, surgery, radiotherapy, other immunotherapies may further enhance outcomes. represent promising strategy overcoming PDAC's resistance conventional therapies, ongoing trials exploring their potential improve long-term survival.

Language: Английский

Citations

0
Next-Generation Vaccines: Leveraging Deep Learning for Predictive Immune Response and Optimal Vaccine Design DOI

K. R. Saranya,

J. L.,

P. Valarmathi

et al.

Journal of Machine and Computing, Journal Year: 2025, Volume and Issue: unknown, P. 768 - 788

Published: April 5, 2025

The rapid advancement in vaccine development has become increasingly critical addressing global health challenges, particularly the wake of emerging infectious diseases. Traditional methods design, while effective, often involve lengthy processes trial and error, which can delay deployment life-saving immunizations. In pursuit enhancing efficacy, application deep learning techniques emerged as a transformative approach. This study presents implementation an Integrated Neural Network Model (INNM), synergistically combines Artificial Networks (ANNs) Random Forests for predictive immune response optimal design. INNM employs hybrid feature selection methodology, integrating Pearson correlation with Recursive Feature Elimination (RFE), to identify most relevant immunological predictors. Implemented Jupyter Notebook environment, model achieved impressive accuracy rate 98.4%, demonstrating its potential revolutionize development. innovative approach underscores capability predict responses high precision, paving way next generation vaccines.

Language: Английский

Citations

0
The Major Role of T Regulatory Cells in the Efficiency of Vaccination in General and Immunocompromised Populations: A Review DOI Creative Commons
Stanislaw M. Stepkowski, Dulat Bekbolsynov,

Jared Oenick

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(9), P. 992 - 992

Published: Aug. 30, 2024

Since their conception with the smallpox vaccine, vaccines used worldwide have mitigated multiple pandemics, including recent COVID-19 outbreak. Insightful studies uncovered complexities of different functional networks CD4 T cells (T helper 1 (Th1); Th2, Th17) and CD8 cytotoxic; Tc), as well B cell (B

Language: Английский

Citations

3
The Major Role of T Regulatory Cells in Efficiency of Vaccination in General and Immunocompromised Populations: A Review DOI Open Access
Stanislaw M. Stepkowski, Dulat Bekbolsynov,

Jared Oenick

et al.

Published: July 22, 2024

Since its conception with the smallpox vaccination, worldwide-used vaccines have thwarted multiple pandemics including recent COVID-19 outbreak. Insightful studies uncovered complexities of different functional networks CD4 T cells [T helper 1 (Th1); Th2, Th17] and CD8 (T cytotoxic; Tc) as well B (BIgM, BIgG, BIgA BIgE) subsets during response to vaccination. Both cell forge central, peripheral tissue-resident It also became apparent that each vaccination formed network regulatory subsets, namely CD4+CD25+Foxp3+ (Treg) interleukin-10 (IL-10)-producing CD4+Foxp3− (Tr1) many others, are shaping quality/quantity vaccine-specific IgM, IgG, IgA antibody production. These components especially critical for immunocompromised patients, such older individuals allograft recipients, their may be ineffective or less effective. This review focuses on presenting how pre- post-vaccination Treg/Tr1 levels influence efficacy. Experimental clinical work revealed involvement evoked immune mechanisms in diminishing vaccine-induced cellular/humoral responses. Alternative steps considered improve by increasing a dose, changing delivery route and/or repeated booster doses vaccines. Vaccination combined anti-CD25 (IL-2Ra chain) anti-PD-1 (programmed death protein) monoclonal (mAb) decrease Tregs boost T/B response. All these data strategies immunizations presented discussed, aiming efficacy humans organ transplant patients.

Language: Английский

Citations

1
Thymic malignancies: role of immunotherapy and novel approaches DOI
Barbara Kiesewetter, Philipp Melhorn, Thorsten Fuereder

et al.

Current Opinion in Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 24, 2024

Purpose of review Thymic epithelial tumors (TETs) are a diverse group malignancies that include thymomas (T), thymic carcinomas (TC), and neuroendocrine tumors. Given the rarity this disease, evidence defining optimal treatment approach in advanced/metastatic setting is limited. This article reviews latest advances systemic therapy for TETs, with special focus on immunotherapy targeted strategies. Recent findings Multiple recent efforts have been made to integrate novel immunotherapies approaches into current algorithm T TC. In addition trials checkpoint inhibitor monotherapy, combinatorial or therapies being explored. Molecular profiling may help identify druggable targets, further optimizing outcomes population. Summary Immune has shown promising activity TETs patients. However, toxicity an unselected cohort, particularly patients, can be substantial, therefore it not recommended outside clinical trials. Until additional research validates biomarkers safely select patients immunotherapy, remain reasonable second-line option. Contemporary next-generation sequencing panels applied targets absence standard treatment.

Language: Английский

Citations

1
Innovative virtual screening of PD-L1 inhibitors: the synergy of molecular similarity, neural networks and GNINA docking DOI
Van-Thinh To, Tieu-Long Phan,

Bao-Vy Ngoc Doan

et al.

Future Medicinal Chemistry, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 12

Published: Sept. 4, 2024

Immune checkpoint inhibitors targeting PD-L1 are crucial in cancer research for preventing cells from evading the immune system.

Language: Английский

Citations

0
Broad applicability of the Goldspire™ platform for the treatment of solid tumors DOI Creative Commons
Jenny Zilberberg,

Christopher Uhl,

Charles Scott

et al.

Clinical Immunology, Journal Year: 2024, Volume and Issue: unknown, P. 110373 - 110373

Published: Sept. 1, 2024

Language: Английский

Citations

0
Next-generation immunotherapy: igniting new hope for lung cancer DOI Creative Commons
Molly Li, Antony C. S. Chan, Kevin Mok

et al.

Therapeutic Advances in Medical Oncology, Journal Year: 2024, Volume and Issue: 16

Published: Jan. 1, 2024

Adoption of immunotherapy has completely transformed the treatment landscape cancer. Patients with advanced cancer treated may benefit from durable tumor response and long-term survival. The most widely used in solid tumors is anti-programmed-death (ligand) protein (PD-(L)1), which now an integral part non-small cell lung (NSCLC) irrespective histological types stage. However, vast majority patients NSCLC anti-PD-(L)1 still develop therapeutic resistance, prognosis after resistance poor. Resistance mechanisms to PD-1 blockade are often complex encompass a combination defects within cancer-immunity cycle. These include failure antigen presentation T-cell priming, presence co-inhibitory immune checkpoints, inability cells infiltrate tumor, immunosuppressive microenvironment. Recently, advances drug design, genomic sequencing, gene editing technologies have led development next-generation immunotherapies that potentially overcome these mechanisms. In this review, we will discuss mechanism four novel modalities detail, namely checkpoint inhibitor targeted therapy combinations, bispecific antibodies, vaccine, therapy. therapeutics all demonstrated early clinical data work synergistically each other restore anticancer immunity. addition, share our perspectives on future promises challenges transformation standard care.

Language: Английский

Citations

0